Applied Therapeutics is a clinical-stage biopharmaceutical company developing therapies for diabetic complications. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) that is being developed for the treatment of diabetic cardiomyopathy, or DbCM, fatal fibrosis of the heart. The company is also developing AT-007, a central nervous system penetrant ARI, for the treatment of galactosemia.